Synonym
II-B08; II-B 08; II-B-08. CD45 Inhibitor V, FAP1 Inhibitor, LMWPTP Inhibitor, Lyp Inhibitor III, PTP1B Inhibitor IX, SHP1 Inhibitor IX.
IUPAC/Chemical Name
3-(1-(3-(Biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid
InChi Key
RATFAFAWIWHLMR-UHFFFAOYSA-N
InChi Code
InChI=1S/C33H27N5O4/c1-37-28-19-29(39)26(33(41)42)18-25(28)31(32(37)23-10-6-3-7-11-23)27-20-38(36-35-27)17-16-30(40)34-24-14-12-22(13-15-24)21-8-4-2-5-9-21/h2-15,18-20,39H,16-17H2,1H3,(H,34,40)(H,41,42)
SMILES Code
O=C(C1=CC2=C(N(C)C(C3=CC=CC=C3)=C2C4=CN(CCC(NC5=CC=C(C6=CC=CC=C6)C=C5)=O)N=N4)C=C1O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
557.61
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sharma N, Everingham S, Zeng LF, Zhang ZY, Kapur R, Craig AW. Oncogenic
KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for
disease progression in mice. Oncotarget. 2014 Aug 15;5(15):6130-41. PubMed PMID:
25026279; PubMed Central PMCID: PMC4171618.
2: Duan YQ, Ma Y, Wang XJ, Jin YY, Wang RL, Dong WL, Xu WR, Kong DX, Wang SQ.
Design potential selective inhibitors for treating cancer by targeting the Src
homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping
approach. Protein Pept Lett. 2014 Jun;21(6):556-63. PubMed PMID: 24364859.
3: Xu J, Zeng LF, Shen W, Turchi JJ, Zhang ZY. Targeting SHP2 for EGFR inhibitor
resistant non-small cell lung carcinoma. Biochem Biophys Res Commun. 2013 Oct
4;439(4):586-90. doi: 10.1016/j.bbrc.2013.09.028. Epub 2013 Sep 13. PubMed PMID:
24041688; PubMed Central PMCID: PMC3822432.
4: Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, Dong Y, Nabinger SC, Wu L,
Gunawan AM, Wang L, Chan RJ, Zhang ZY. Salicylic acid based small molecule
inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine
phosphatase-2 (SHP2). J Med Chem. 2010 Mar 25;53(6):2482-93. doi:
10.1021/jm901645u. PubMed PMID: 20170098; PubMed Central PMCID: PMC2842125.
